Effects of empagliflozin on right ventricular free-wall strain in patients with heart failure and reduced ejection fraction: results from the Empire HF Trial
ESC Heart Failure · 05.05.2026 · 13 (3)
DOI: 10.1093/eschf/xvaf031 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift ESC Heart Failure, online erschienen am 08.01.2026. Verfasst von Massar Omar und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Odense University Hospital, J. B. Winsløws Vej 4, Odense C 5000, Denmark. Hauptthemen laut MEDLINE: Heart Failure, Benzhydryl Compounds, Stroke Volume, Glucosides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Danish Heart Foundation, Steno Diabetes Center Odense, Denmark, A.P. Møller Foundation for the Advancement of Medical Science.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Introduction
To investigate the effect of empagliflozin on right ventricular (RV) function in patients with heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve outcomes and reverse left ventricular (LV) remodelling in HFrEF. The impact on RV function remains uncertain.
Methods
The Empire HF trial was an investigator-initiated, double-blind, randomized, placebo-controlled trial of 190 participants with a left ventricular ejection fraction (LVEF) of 40% or lower, with New York Heart Association (NYHA) Class I−III symptoms. Participants were randomized to receive either empagliflozin (at a dose of 10 mg once daily) or placebo, on top of recommended therapy for 12 weeks. The primary endpoint of this exploratory substudy was changes in RV free wall strain (RVFWS) across the whole cohort. RVFWS was also stratified into tertiles based on baseline RVFWS. Secondary endpoints included changes in tricuspid annular plane systolic excursion (TAPSE) and RV S’ velocity.
Results
Between June 2017 and September 2019, a total of 190 patients were enrolled, of whom 160 were included in this substudy. Baseline characteristics were balanced between the groups (mean age of 64 ± 11 years, 86% male, mean LVEF: 29 ± 8%, 79% in NYHA Class II, 83 patients (52%) had an implanted cardiac device, and tricuspid valve regurgitation was absent/trace in 136 (85%) and mild in 24 (15%)). A high proportion of the population were on optimal medical treatment for HFrEF, and device therapy remained unchanged during follow-up. The overall mean RVFWS was −16.7 ± 6.1%, with the empagliflozin group at −16.4 ± 6.2% and the placebo group at −16.9 ± 5.9%. No differences were observed in RVFWS between the groups. When stratified by baseline RVFWS into tertiles, patients in the lowest tertile demonstrated a significant improvement with empagliflozin (treatment effect: −2.9% [95% CI: −5.0 to −0.3]; P = .027). This finding was independent of LVEF, plasma volume, and weight loss, and remained unchanged after additional adjustment for LV remodelling and the presence of resynchronization therapy. No significant treatment effect was observed in the middle or highest tertiles of RVFWS, nor in the overall or lowest tertiles of TAPSE or RV S’.
Conclusion
This exploratory substudy of the Empire HF, treatment with empagliflozin exerted no overall effect on RV function in stable HFrEF patients, but significantly improved RVFWS in patients in the lowest tertile of RVFWS after 12 weeks of treatment. Trial Registration ClinicalTrials.gov, Unique Identifier: NCT03198585
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Odense University Hospital, J. B. Winsløws Vej 4, Odense C 5000, Denmark.
- Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
- Steno Diabetes Centre Odense, Odense University Hospital, Odense Denmark.
- Department of Cardiology, Herlev and Gentofte University Hospital, Copenhagen, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Department of Endocrinology, Rigshospitalet, Copenhagen, Denmark.
ORCID-Profile: Massar Omar, Mulham Ali, Caroline Kistorp, Lars Videbæk, Finn Gustafsson, Lars Køber, Morten Schou
Förderung
- Danish Heart Foundation
- Steno Diabetes Center Odense, Denmark
- A.P. Møller Foundation for the Advancement of Medical Science
- Research Council at Herlev and Gentofte University Hospital, Denmark
- Research and Innovation Foundation of the Department of Cardiology
- Herlev and Gentofte University Hospital, Denmark
- Capital Region of Denmark
Zitieren
APA
Omar, M., Jensen, J., Ali, M., Frederiksen, P. H., Kistorp, C., Videbæk, L., Poulsen, M. K., Tuxen, C. D., Borlaug, B. A., Möller, S., Gustafsson, F., Køber, L., Schou, M., & Møller, J. E. (2026). Effects of empagliflozin on right ventricular free-wall strain in patients with heart failure and reduced ejection fraction: results from the Empire HF Trial. ESC Heart Failure, 13(3). https://doi.org/10.1093/eschf/xvaf031
Vancouver
Omar M, Jensen J, Ali M, Frederiksen PH, Kistorp C, Videbæk L, et al. Effects of empagliflozin on right ventricular free-wall strain in patients with heart failure and reduced ejection fraction: results from the Empire HF Trial. ESC Heart Failure. 2026;13(3). doi:10.1093/eschf/xvaf031
BibTeX
@article{Omar2026,
author = {Omar, Massar and Jensen, Jesper and Ali, Mulham and Frederiksen, Peter H and Kistorp, Caroline and Videbæk, Lars and Poulsen, Mikael Kjær and Tuxen, Christian D and Borlaug, Barry A and Möller, Sören and Gustafsson, Finn and Køber, Lars and Schou, Morten and Møller, Jacob Eifer},
title = {Effects of empagliflozin on right ventricular free-wall strain in patients with heart failure and reduced ejection fraction: results from the Empire HF Trial},
journal = {ESC Heart Failure},
year = {2026},
volume = {13},
number = {3},
doi = {10.1093/eschf/xvaf031}
}
EUVIMED